Index

Note: Page numbers in bold represent tables, those in italics represent figures.

ABO blood groups 131
ABO haemolytic disease of newborn 30, 31
ABO incompatibility 19, 85–7, 86, 87
ABO-related haemolytic disease of newborn 30, 31
acidosis 58
ADAMTS 13 42
adult stem cells 108
adult T-cell leukaemia virus 76–7
AIDS 50, 76
albumin 48, 76
binding to 49
clinical associations 49, 49
clinical properties 48–9, 49
crystalloid vs colloid 51–2, 51, 52
effect of illness 49
indications for use 50–51, 50, 51
physiology 48
prognostic value 50, 50
albumin solutions 48
alloimmune thrombocytopenia 24
arm cleansing 71
anti-A antibodies 61, 62
anti-AB antibodies 61, 62
anti-B antibodies 61, 62
anti-AB antibodies 61, 62
anti-A antibodies 61, 62
arm cleansing 71
dilutional thrombocytopenia 24
dilutional thrombocytopenia 24
Duffy antibodies 11
audit 100–102
cardiac surgery 24
caudal block 37
Cary's test 77
cation of hypovolaemic
coagulopathy 57–8, 97
crystalloid osmotic pressure 48
Cytomegalovirus 4, 25, 69, 77
DDAVP, see desmopressin
desmopressin 45, 93
dilutional thrombocytopenia 24
2,3-diphosphoglycerate 18
dilutional thrombocytopenia 24
Duffy antibodies 11
education 114
electronica 13
electronica 13
EC Blood Directive (2004/33/EC) 2
EDTA 10
embryonic stem cells 108
electronica 13
electronica 13
ethylenediaminetetra-acetic acid see EDTA
European Union Blood Directive 2005 111–14,
111, 112–14
areas of impact 111
factor VII, recombinant activated 59
factor VIII, recombinant 45, 93–4
factor VIII concentrate 44–5
factor IX concentrate 44–5
factor XIII concentrate 45
fetal blood sampling 33–5
fetal blood sampling 33–5
fetal transfusion 33–5
platelet transfusion 35
red cell transfusion 33–5, 34
fetomaternal haemorrhage 28–9

blood
groups 9, 11, 12, 13
ordering for surgery 13–14, 14
blood loss 54
blood prescription chart 11
Blood Safety and Quality Regulations 2005 2
blood stocks management 8, 8
blood substitutes 95–8
haemoglobin-based 96–7, 97
need for 95
properties of 95
reverse 10
blood supply 6–8, 6, 7
blood usage, impact of vCJD on 81–2
dilutional thrombocytopenia 24
bone marrow failure 23–24, 25
dilutional thrombocytopenia 24

Coagulation factors

creatinine

Dilutional thrombocytopenia 57–8, 97
DDAVP, see desmopressin
desmopressin 45, 93
ethylenediaminetetra-acetic acid see EDTA
European Union Blood Directive 2005 111–14,
111, 112–14
areas of impact 111
factor VII, recombinant activated 59
factor VIII, recombinant 45, 93–4
factor VIII concentrate 44–5
factor IX concentrate 44–5
factor XIII concentrate 45
fetal blood sampling 33–5
fetal transfusion 33–5
platelet transfusion 35
red cell transfusion 33–5, 34
fetomaternal haemorrhage 28–9
contrasdas
immunoglobulins 45–6
indications for use 42
prothrombin complex concentrates 45
plasma proteins, reactions to 67, 67
platelets 7, 7
platelet concentrates
preparation of 22–3
properties of 23
platelet function abnormalities 24
platelet incompatibility 66–7
platelet recovery 24–5
platelet transfusions 22–5
administration 24–5
adverse effects 25
antigen matched 25
contraindications 25
crossmatched 24
fetal 35
indications 23–4, 24
neonate 36
PolyHeme 97
post-transfusion purpura 25
pregnancy, blood grouping/antibody screening 31–2, 31
preoperative anaemia 89–90, 89
prion diseases 77, 79–80, 79, 80
see also Creutzfeldt–Jakob disease, new variant
prothrombin complex concentrates 45
PTP see post-transfusion purpura
purpura, post-transfusion 67
quality systems 113
Red Book 113
red cells 6–7, 7, 16
alloantibodies 20
preparation 15
storage 15–16, 16, 17
uses 16
red cell antigens, population frequency 13
red cell incompatibility 61–4
circumstances 62–3
haemolytic transfusion reactions 62, 62
acute 61
delayed 64, 64
mechanisms of red cell destruction 63, 63
naturally occurring and immune antibodies 61–2, 62
symptoms and signs 63–4, 63
red cell salvage 90–92
automated 91–2, 91, 92
collection and reinfusion of wound
fetal drainage 90–91, 90
labelling 94
red cell transfusions 15–21
administration 17–18
adverse effects 19–20, 20, 21
emergency 20–21
expected benefits 18–19
fetal 33–5, 34
indications for 17
neonate 35–6, 35, 36
rational for use 16–17
recipients 15
transfusion thresholds 3
regulatory issues 110–16
future action 115–16
need for regulation 110, 110
regulatory framework 111–15, 111
see also individual regulations
reverse blood grouping 10
RhD antigen 11
RhD haemolytic disease of the newborn 27
RhD prophylaxis 28
RhD sensitization 27, 28
saline adenine glucose mannitol (SAG-M) 15, 17, 35
Saline versus Albumin Fluid Evaluation (SAFE) study 50, 51, 52
Serious Adverse Blood Reactions and Events 50, 71
Serious Hazards of Transfusion (SHOT) 19, 20, 40, 71, 83–8, 114
Serious Hazards of Transfusion (SHOT) 19, 20, 40, 71, 83–8, 114
blood safety issues 84–5, 85
categories of adverse reactions 84
development of safety culture 87–8
frequency of adverse reactions 85
lessons from 83–4, 84
operation of 83, 84
prevention of incompatibility reactions 85–7, 86, 87
role of information technology 87
serological testing 5
SHOT see Serious Hazards of Transfusion spherocytosis 30
stem cells, non-haemopoietic 108–9
stem cell plasticity 108–9
stem cell transplantation 104–6, 104, 105, 106
supply and demand 6–9
surgery
operative haemostasis 90
ordering blood for 13–14, 14
thrombocytopenia 22, 57
alloimmune 24
dilutional 24
transfusion-associated graft-versus-host disease (TA-GVHD) 20, 24, 34, 65, 84, 85
transfusion reactions 10, 13, 19, 20, 25, 40, 61, 62, 65, 81
thromboelastography 58–9, 58, 59
T lymphocytes 107, 108
topical haemostatic sealants 93
traceability 113–14
instructions 113
tag 112
training 114
TRALI see transfusion-related acute lung injury
tranexamic acid 92
transfusion reaction 19–21, 20, 21
transfusion recipients
age of 16
safety of 2
transfusion-related acute lung injury (TRALI) 20, 40, 65–6, 65, 66
transfusion-related mortality/morbidity 85
transmissible spongiform encephalopathies see prion diseases
T regulatory cells 108
Treponema pallidum (syphilis) 72, 72
Trypanosoma cruzi 69, 71
UK Blood and Quality Safety Regulations 2005 114
UK Haemophilia Centre Doctors’ Organisation (UKHCDO) 41
UK Operational Impact Group 112
urticaria 19, 67
vCJD see Creutzfeldt–Jakob disease, variant CJD
viral contamination by transfusion 74–8
adult T-cell leukaemia virus 76–7
cytomegalovirus 77
hepatitis B virus 74–5, 74, 75
hepatitis C virus 75–6, 75
HIV 76, 76, 77
human T-cell leukaemia virus 76–7
parvovirus B19 77
viral inactivation 74, 75
volume overload 20
von Willebrand factor 44
von Willebrand’s disease 45
West Nile virus 1
white cell incompatibility 4–6
graft-versus-host disease 66
non-haemolytic febrile transfusion reactions 65
transfusion-related acute lung injury 65–6, 65, 66